Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Samad Oraee

Pain Medicine Woodbridge, VA Medical Doctor

NPI 1235156084 CMS profile 192300

2050 Old Bridge Rd, Ste 200, Woodbridge, VA 22192

Open in the dashboard

General payments

$8,258

210 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, Samad Oraee of Woodbridge, VA is reported in the CMS Open Payments database as having received $8,258 across 210 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $1,259 73
2020 General $5,817 63
2019 General $1,181 74

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Samad Oraee
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Samad Oraee were reported at $0. Among 757 Pain Medicine profiles paid that year, the median was $470 and the middle half received between $146 and $1,462.

Show as a table
Year Samad Oraee Pain Medicine median Middle half National median
2019 $1,181 $506 $144–$1,566 $163
2020 $5,817 $315 $96–$934 $114
2021 $1,259 $452 $134–$1,237 $132
2022 $0 $475 $124–$1,407 $149
2023 $0 $480 $136–$1,384 $160
2024 $0 $521 $164–$1,511 $164
2025 $0 $470 $146–$1,462 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. Allergan Inc. $4,990 18 payments
  2. Collegium Pharmaceutical, Inc. $473 32 payments
  3. Scilex Pharmaceuticals Inc. $312 16 payments
  4. Teva Pharmaceuticals USA, Inc. $304 11 payments
  5. Lilly USA, LLC $288 17 payments
  6. Amgen Inc. $265 12 payments
  7. Supernus Pharmaceuticals, Inc. $224 12 payments
  8. AbbVie, Inc. $143 12 payments
  9. Novartis Pharmaceuticals Corporation $135 9 payments
  10. Daiichi Sankyo Inc. $123 14 payments
  11. Other $1,002 57 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Food and Beverage $3,790 204 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,325 3 payments
  3. Travel and Lodging $1,139 2 payments
  4. Education $4 1 payment
Products named General payments · program years 2019–2021
  1. UBRELVY Neuroscience $4,990 18 payments
  2. XTAMPZA $469 31 payments
  3. AIMOVIG $399 21 payments
  4. EMGALITY $288 17 payments
  5. ZTLido $240 12 payments
  6. REYVOW $217 12 payments
  7. AJOVY $190 6 payments
  8. TROKENDI XR $185 10 payments
  9. UBRELVY Neuroscience $143 12 payments
  10. Morphabond ER $123 14 payments
  11. Other $1,378 82 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

210 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record